Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

August 31, 2020

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Cisplatin

DRUG

Paclitaxel

Trial Locations (20)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center-Sleepy Hollow, Sleepy Hollow

10604

Memorial Sloan Kettering Cancer Center-West Harrison, Harrison

11570

Memorial Sloan Kettering Cancer Center-Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center-Commack, Commack

15213

Universtiy of Pittsburgh- Magee-Womens Hospital, Pittsburgh

21287

Johns Hopkins University, Baltimore

27599

University of North Carolina- Lineberger Cancer Center, Chapel Hill

27710

Duke University, Durham

35294

University of Alabama, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

46202

Indiana University- Simon Cancer Center, Indianapolis

77030

Baylor College of Medicine, Houston

98034

Seattle Cancer Alliance at EvergreenHealth, Kirkland

98195

University of Washignton, Seattle

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02190

South Shore Hospital, Weymouth

07920

Memorial Sloan Kettering Cancer Center-Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Cancer Center-Monmouth, Middletown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Myriad Genetics, Inc.

INDUSTRY

collaborator

Translational Breast Cancer Research Consortium

OTHER

lead

Dana-Farber Cancer Institute

OTHER